RONALD BERENSON, M.D.
Medical Laboratory at 41 Ave, Seattle, WA

5635387, Jun 3, 1997

Apr 3, 1995

8/415752

Rui G. Fei - Seattle WA
Shelly Heimfeld - Woodinville WA
Billy W. Minshall - Mill Creek WA
Ronald J. Berenson - Mercer Island WA

CellPro, Inc. - Bothell WA

C12N 500, C12N 502, A61K 3514

435378

Methods for increasing the number of human hematopoietic precursor cells in vitro are provided. The methods generally comprise (a) separating human hematopoietic precursor cells from mature hematopoietic cells present in a blood product; (b) inoculating the separated precursor cells into a culture vessel containing a culture medium comprising a nutritive medium and a source of growth factors at a density of between 1. times. 10. sup. 3 cells/ml and 4. times. 10. sup. 6 cells/ml; and (c) culturing the cells under conditions and for a time sufficient to increase the number of precursor cells relative to the number of such cells present in the blood product. The culture medium may also include a suitable amount of microcarrier beads. Suitable blood products include bone marrow, umbilical cord blood, and peripheral blood. A device for carrying out such methods is also provided.

2010027, Oct 28, 2010

Jul 7, 2009

12/459862

Mir Imran - Los Altos Hills CA, US
Mir Hashim - Fremont CA, US
Sanjay Patel - Palo Alto CA, US
Ronald J. Berenson - Mercer Island WA, US

A61K 33/42, A61K 33/26, A61P 7/06

424604, 424646

Embodiments provide devices, systems and methods for the transdermal delivery of chelated compounds. One embodiment provides a method for the iontophoretic transdermal delivery of a chelated iron complex for the treatment of anemia. A first patch comprising an active electrode and a chelated iron complex is applied to the skin; a second patch containing an electrode is also applied. An electrical current is then delivered to the skin from the active electrode. The chelated complex is transported across the skin via electromotive force from the current, with the iron being substantially chromogenically unreactive with the skin during transport so that there is little or no tattooing of the skin due to the formation of insoluble oxidative products. The complex is then dissociated by phagocytosis or related process to release the iron where it may be bound by transferrin or ferritin and carried to other sites for storage or metabolic use.

2010025, Oct 7, 2010

Mar 31, 2010

12/751943

André Lieber - Seattle WA, US
Hongjie Wang - Seattle WA, US
Ronald Jay Berenson - Mercer Island WA, US
Darrick Carter - Seattle WA, US

UNIVERSITY OF WASHINGTON - Seattle WA
COMPLIMENT CORPORATION - Mercer Island WA

A61K 39/395, C07K 7/08, C07K 7/06, A61K 38/06, A61K 38/08, A61K 38/10, C07K 5/08, C07K 14/00, A61K 38/16, A61K 35/76, C12N 15/63, C40B 30/04, C07H 21/04, C07K 16/30, A61P 35/00

4241741, 530326, 530327, 530328, 530329, 530330, 530331, 530324, 514 193, 4241301, 4241781, 424 936, 4353201, 506 9, 536 231, 5303897

This invention relates to agents capable of reducing the activity, amount or density of complement regulatory proteins (CRPs) on target cells. The invention also provides methods of identification of such agents, methods of making, and uses thereof.

2005015, Jul 14, 2005

Dec 2, 2004

11/001921

Ronald Berenson - Mercer Island WA, US
Che Law - Shoreline WA, US
Mark Bonyhadi - Issaquah WA, US
Narinder Saund - Seattle WA, US
Stewart Craig - Issaquah WA, US
Alan Hardwick - Seattle WA, US
Dale Kalamasz - Redmond WA, US
David McMillen - Seattle WA, US
Harjinder Chana - Issaquah WA, US

XCYTE Therapies, Inc. - Seattle WA

C12N005/08

435372000

The present invention relates generally to methods for activating and expanding cells, and more particularly, to a novel method to activate and/or stimulate cells that maximizes the expansion of such cells to achieve dramatically high densities. In the various embodiments, cells are activated and expanded to very high densities in a short period of time. In certain embodiments, cells are activated and expanded to very high numbers of cells in a short period of time. Compositions of cells activated and expanded by the methods herein are further provided.

2002001, Feb 14, 2002

May 24, 2001

09/864930

Ronald Berenson - Mercer Island WA, US

C12N005/08, A61K045/00

435/372000, 424/093700, 424/144100

The present invention relates generally to methods for restoring or enhancing T-cell immune surveillance, and more particularly, to a method treating an immuno-compromised, immuno-deficient, or immuno-suppressed animal by infusion of peripheral blood lymphocytes, T-cells, or activated T-cells.

2005021, Sep 29, 2005

Nov 8, 2004

10/984351

Ronald Berenson - Mercer Island WA, US
Che Law - Shoreline WA, US
Mark Bonyhadi - Issaquah WA, US
Narinder Saund - Seattle WA, US
Stewart Craig - Issaquah WA, US
Alan Hardwick - Seattle WA, US
Dale Kalamasz - Redmond WA, US
David McMillen - Seattle WA, US
Harjinder Chana - Issaquah WA, US

XCYTE Therapies, Inc. - Seattle WA

C12N005/08

435372000

The present invention relates generally to methods for activating and expanding cells, and more particularly, to a novel method to activate and/or stimulate cells that maximizes the expansion of such cells to achieve dramatically high densities. In the various embodiments, cells are activated and expanded to very high densities in a short period of time. In certain embodiments, cells are activated and expanded to very high numbers of cells in a short period of time. Compositions of cells activated and expanded by the methods herein are further provided.

2003008, May 1, 2003

Apr 29, 2002

10/136024

Ronald Berenson - Mercer Island WA, US
Mark Bonyhadi - Issaquah WA, US
Stewart Craig - Issaquah WA, US
Dale Kalamasz - Redmond WA, US
Tatsue Monji - Seattle WA, US

XCYTE Therapies, Inc. - Seattle WA

A61K048/00, C12N005/08

435/372000, 424/093210

The present invention relates to methods for maturing antigen-presenting cells, and more particularly, to methods for maturing dendritic cells. Methods for generating mature and/or maturing antigen-presenting cells in vitro and in vivo are disclosed. The present invention also relates to compositions of cells, including mature antigen-presenting cells and/or activated T cells and their use in generating immune responses in vivo, and inhibiting the development of or preventing infectious diseases and cancers.

2005022, Oct 13, 2005

Mar 28, 2005

11/091361

Mark Bonyhadi - Issaquah WA, US
Ronald Berenson - Mercer Island WA, US

XCYTE Therapies, Inc. - Seattle WA

A61K045/00, C12N005/08

424093700, 435372000

The present invention relates to compositions and methods for the use of T cells and more particularly, activated T cells, in the treatment and/or amelioration of diseases associated with a proinflammatory state, such as cachexia, chronic diseases such as chronic renal failure, and hepatitis.

2011003, Feb 10, 2011

Jul 12, 2010

12/834720

Ronald J. Berenson - Mercer Island WA, US
Patrick Bobbitt - Seattle WA, US
Zhongping Lin - Wilimington DE, US

HEMAQUEST PHARMACEUTICALS, INC. - Seattle WA

G01N 33/50

436129

Described herein is a method of detecting and/or quantifying analytes, such as short-chain fatty acids. Analysis for the presence and/or quantity of the small molecule can be performed on a biological sample from a subject. In some embodiments, a liquid chromatography/mass spectrometry (LC-MS/MS) instrumentation is combined with a solid-phase extraction (SPE). Methods of derivatization can also be incorporated with LC-MS/MS and SPE instrumentation to detect and quantify target analytes. In addition to derivation, methods of reconstituting derivatized molecules can also be incorporated with LC-MS/MS and SPE instrumentation to detect and quantify target analytes.

2003011, Jun 26, 2003

Jun 28, 2002

10/187467

Ronald Berenson - Mercer Island WA, US
Che Law - Shoreline WA, US
Mark Bonyhadi - Issaquah WA, US
Narinder Saund - Seattle WA, US
Stewart Craig - Issaquah WA, US
Alan Hardwick - Seattle WA, US
Dale Kalamasz - Redmond WA, US
David McMillen - Seattle WA, US
Harjinder Chana - Issaquah WA, US

XCYTE Therapies, Inc. - Seattle WA

C12N005/08

435/372000

The present invention relates generally to methods for activating and expanding cells, and more particularly, to a novel method to activate and/or stimulate cells that maximizes the expansion of such cells to achieve dramatically high densities. In the various embodiments, cells are activated and expanded to very high densities in a short period of time. In certain embodiments, cells are activated and expanded to very high numbers of cells in a short period of time. Compositions of cells activated and expanded by the methods herein are further provided.